AMG 510

Pipeline

Status by Indication[2][1]

Competition

Competitive Landscape

Lung CancerLung Carcinoma

206 competitors in Lung Cancer

#DrugCompanyPhaseTrials

1

Beyfortus

BeiGene

Phase 3

102

Abraxane

Bristol-Myers Squibb

Phase 3

73

Alecensa

Roche

Phase 3

34

Ilaris

Novartis

Phase 3

25

Verzenio

Eli Lilly

Phase 3

26

Lynparza

AstraZeneca

Phase 3

27

DATROWAY

Daiichi Sankyo

Phase 3

28

Zepzelca

Jazz Pharmaceuticals

Phase 3

29

Tarlatamab-Dznl

Amgen

Phase 3

210

Hycamtin

MMeitheal

Phase 3

6Show 33 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Small Cell Lung Cancer1 trial

A Multicenter, Open-label, Single-arm, Expanded Access Protocol of Sotorasib for the Treatment of Subjects With Previously Treated Locally Advanced Unresectable/Metastatic NSCLC With KRAS p.G12C Mutation

No longer available·Amgen··NCT04667234

KRAS p, G12c Mutated /Advanced Metastatic NSCLC1 trial

A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C

Completed·Amgen·Phase 3·NCT04303780·345 enrolled

Lung Cancer1 trial

A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05118854·13 enrolled

Details

Drug Info

Related News